•Physician •Internal Medicine •Ex becario Ruta Quetzal
- Tweets809
- Following389
- Followers130
- Likes736
ALT Two graphs show the change in ESSDAI score over time (full analysis population) for the NEPTUNUS-1 trial (Panel A) and NEPTUNUS-2 trial (Panel B).
ALT Two forest plots showing the primary and key secondary efficacy end points (full analysis population) for the NEPTUNUS-1 trial (Panel A) and the NEPTUNUS-2 trial (Panel B).
ALT Bilateral auricular swelling (A) and flaccid auricular deformity (B). Chest CT demonstrated tracheal wall thickening with airway collapse (C). 18F-FDG PET/CT showed increased uptake in multiple cartilaginous sites, including the arytenoid cartilages and costochondral junctions, with diffuse marrow activity (D)
ALT Comparative Effectiveness of Tocilizumab and Tumor Necrosis Factor Inhibitors in Takayasu Arteritis: Age-Related Differences in Treatment Response. Graphical abstract created using BioRender
ALT B-cell Maturation Antigen (BCMA)-CAR-T Therapy in a Patient with Triple Positive Antiphospholipid Syndrome and Recurrent Alveolar Bleeding. Graphical abstract made using BioRender
ALT This bar chart compares the percentage of patients receiving obinutuzumab and tacrolimus across three time points: Week 52, Week 76, and Week 104.
ALT A graph showing patient relapse-free rates over 104 weeks. The y-axis shows the percentage of patients relapse-free, while the x-axis represents weeks. Two curves are present: one in blue for obinutuzumab and another in gray for tacrolimus. A table below indicates the number of patients at risk for both treatments.
ALT IFNα and oligoprotein IFN signatures in Sjögren’s disease
